Long-Term Effects and Prognosis in Acute Heart Failure Treated with Tolvaptan: The AVCMA Trial
Table 1
Comparisons of clinical characteristics between tolvaptan and carperitide groups.
Tolvaptan
Carperitide
( = 52)
( = 53)
Age (years)
74.6 ± 11.4
75.1 ± 10.4
Gender (male/female)
28/24
31/22
Body weight (kg)
58.2 ± 12.9
57.0 ± 11.7
Body mass index (kg/m2)
24.0 ± 4.3
22.5 ± 3.1
Etiology of chronic heart failure, (%)
Dilated cardiomyopathy
21 (40)
22 (42)
Ischemic heart disease
13 (25)
13 (25)
Valvular heart disease
6 (12)
5 (9)
Hypertensive heart disease
5 (10)
6 (11)
Other
7 (13)
7 (13)
Heart rate (/min)
90.0 ± 25.6
86.7 ± 25.9
Systolic blood pressure (mmHg)
130.0 ± 25.8
129.1 ± 26.5
Diastolic blood pressure (mmHg)
75.5 ± 15.4
73.9 ± 18.4
Echocardiography
LVEDD (mm)
52.4 ± 10.7
53.0 ± 8.8
LVEF (%)
46.7 ± 17.1
44.7 ± 14.2
IVC (mm)
19.4 ± 5.7
18.7 ± 5.6
BNP* (pg/mL)
544.3 (410.7)
599.0 (400.9)
Blood urea nitrogen (mg/dL)
24.4 ± 14.8
24.5 ± 12.6
Serum creatinine (mg/dL)
1.19 ± 0.75
1.23 ± 0.75
Estimated GFR (mL/min/1.73 m2)
52.4 ± 21.8
50.0 ± 21.2
Serum sodium (mEq/L)
139.7 ± 5.4
140.2 ± 3.5
Serum potassium (mEq/L)
4.1 ± 0.6
4.2 ± 0.6
LVEDD, left ventricular end diastolic diameter; LVEF, left ventricular ejection fraction; BNP, B-type natriuretic peptide; GFR, glomerular filtration rate. *Skewed data are reported as median (interquartile range).
